Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/2007
06/21/2007WO2007070683A2 Certain chemical entities, compositions and methods
06/21/2007WO2007070667A2 Crystal form of atorvastatin hemi-calcium and processes for preparation thereof
06/21/2007WO2007070632A2 Abuse resistant transmucosal drug delivery device
06/21/2007WO2007070626A2 Certain chemical entities, compositions and methods
06/21/2007WO2007070617A1 Bioabsorbable implant of hyaluronic acid derivative for treatment of osteochondral and chondral defects
06/21/2007WO2007070613A2 Rifamycin analogs and uses thereof
06/21/2007WO2007070599A2 Chemoprotective methods and compositions
06/21/2007WO2007070569A2 Composition and regimen for the treatment of epidermal herpetic lesions
06/21/2007WO2007070547A2 Treatment of arthritis and other musculoskeletal disorders with crosslinked hyaluronic acid
06/21/2007WO2007070546A2 Meniscal implant of hyaluronic acid derivatives for treatment of meniscal defects
06/21/2007WO2007070536A2 7-quinolyl ketolide antibacterial agents
06/21/2007WO2007070514A1 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
06/21/2007WO2007070506A2 Diaza heterocyclic sulfonamide derivatives and their uses
06/21/2007WO2007070504A2 Stable and palatable oral liquid sumatriptan compositions
06/21/2007WO2007070494A2 Heterocycles and derivatives thereof and methods of manufacture and therapeutic use
06/21/2007WO2007070463A2 Compositions, methods and kits for removing debris from an ocular area
06/21/2007WO2007070444A1 Lestaurtinib crystalline form 1, crystalline lestaurimib anhydrate and amorphous lestaurimib
06/21/2007WO2007070434A2 Fused aminopiperidines as dipeptidyl peptidase-4 inhibitors for the treatment or prevention of diabetes
06/21/2007WO2007070433A2 2-arylthiazole derivatives as cxcr3 receptor modulators
06/21/2007WO2007070430A2 Identification and application of antibiotic synergy
06/21/2007WO2007070426A2 Sexual dysfunction
06/21/2007WO2007070425A2 Use of low-dose ladostigil for neuroprotection
06/21/2007WO2007070423A2 Topical glucocorticosteroid formulations
06/21/2007WO2007070413A1 Treatment of corneal ulcers with topical gatifloxacin
06/21/2007WO2007070398A1 Polycyclic indazole derivatives that are erk inhibitors
06/21/2007WO2007070362A1 Indolone compounds useful to treat cognitive impairment
06/21/2007WO2007070319A2 Dibenzonaphthyridine derivatives and methods of use thereof
06/21/2007WO2007070307A2 Intravenous essential fatty acid emulsion
06/21/2007WO2007070201A1 Aspartic protease inhibitors
06/21/2007WO2007070173A2 Cetp inhibitors
06/21/2007WO2007070164A1 Pharmaceutical composition comprising a proton pump inhibitor, a buffering agent and an anti-h. pylori active substance and methods of using same
06/21/2007WO2007070135A1 Compounds
06/21/2007WO2007070084A1 Uses of rifamycins
06/21/2007WO2007069986A1 New oxabispidine compounds for the treatment of cardiac arrhythmias
06/21/2007WO2007069983A1 Method for extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein from blood
06/21/2007WO2007069978A1 Novel n-(fluoro-pyrazinyl)-phenylsulfonamid.es as moodulators of chemokine receptor ccr4.
06/21/2007WO2007069977A1 Alkylsulphonamide quinolines
06/21/2007WO2007069924A1 Deazapurine analogs of 4'-aza-l-nucleosides
06/21/2007WO2007069923A1 Deazapurine analogs of 1'-aza-l-nucleosides
06/21/2007WO2007069900A1 Use of soluble dietary fibres against muscle wasting
06/21/2007WO2007069773A1 A pharmaceutical composition comprising an amide derivative
06/21/2007WO2007069758A1 Composition having ppar ligand activity
06/21/2007WO2007069744A1 Composition for prevention/amelioration of metabolic syndrome
06/21/2007WO2007069727A1 Agent for prevention and treatment of acute renal failure
06/21/2007WO2007069716A1 Composition having effect of inhibiting visceral fat accumulation
06/21/2007WO2007069712A1 Amine compound and use thereof for medical purposes
06/21/2007WO2007069675A1 Easily absorbed oral preparation containing xanthine derivative
06/21/2007WO2007069671A1 Bicyclic heterocyclic compound
06/21/2007WO2007069669A1 Pharmaceutical composition for enhancing adiponectin production
06/21/2007WO2007069661A1 Bisoprolol-containing adhesive patch
06/21/2007WO2007069635A1 Vla-4 inhibitory drug
06/21/2007WO2007069621A1 Novel composition and method for production thereof
06/21/2007WO2007069603A1 Physiologically active glycolipid
06/21/2007WO2007069565A1 Bicyclic heterocyclic compound
06/21/2007WO2007069555A1 Novel 16-membered cyclic 4”-0-carbamoyl azalide derivative and process for producing same
06/21/2007WO2007069468A1 Cytokine secretion promoter
06/21/2007WO2007069378A1 Drug package
06/21/2007WO2007069358A1 Novel preparation of gastric retention type
06/21/2007WO2007069275A2 Optical fiber having reduced hydrogen induced loss and the method for producing the same
06/21/2007WO2007069254A2 POLYMORPHS AND AMORPHOUS FORMS OF 5-AMINO-l-[2,6- DICHLORO-4-(TRIFLUOROMETHYL)PHENYL]-4- [(TRIFLUOROMETHYL)SULFINYL]-IH-PYRAZOLE-3-CARBONITRILE
06/21/2007WO2007069070A2 Aseptically filled multidose injectable dosage forms of granisetron
06/21/2007WO2007069068A2 Cell penetrating peptide conjugates for delivering nucleic acids into cells
06/21/2007WO2007069053A1 Benzimidazole antagonists of the h-3 receptor
06/21/2007WO2007069050A2 Processes for the preparation of alfuzosin
06/21/2007WO2007068948A2 Pharmaceutical sustained release compositions comprising in particular thyroid hormones
06/21/2007WO2007068929A1 Cyclic amine derivatives and their uses
06/21/2007WO2007068905A1 1,2,4-TRIAZOL-l-YL BISPHENYL DERIVATIVES FOR USE IN THE TREATMENT OF ENDOCRINE-DEPENDENT TUMOURS
06/21/2007WO2007068895A1 Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or flt1 antagonist for treating cancer
06/21/2007WO2007068844A1 Use of a dermatological composition comprising an association of hydroquinone, fluocinolone acetonide and tretinoin for treating skin hyperpigmentation following psoriasis or eczema
06/21/2007WO2007068843A1 Use of a dermatological composition comprising an association of hydroquinone, fluocinolone acetonide and tretinoin, for whitening non-caucasian skin types
06/21/2007WO2007068842A1 Use of a dermatological composition comprising an association of hydroquinone, fluocinolone acetonide and tretinoin, in combination with the application of laser or pulsed flash lamp radiation for treating acquired dermal melanocytosis
06/21/2007WO2007068841A2 Use of a composition based on tretinoin, hydroquinone and fluocinolone acetonide, accompanied by a chemical peeling
06/21/2007WO2007068829A1 Orodispersible pharmaceutical composition for oral, oromucosal or sublingual administration of agomelatine
06/21/2007WO2007068776A1 Antitumour compounds
06/21/2007WO2007068773A1 Product for use in the prevention and treatment of cardiovascular diseases, cancer and chronic inflammatory diseases
06/21/2007WO2007068754A1 Dibenzene derivatives as calcium channel blockers
06/21/2007WO2007068743A1 Use of polyunsaturated compounds as whitening agents
06/21/2007WO2007068739A1 4-amino-benzamide derivatives as 5-ht4 receptor agonists for the treatment of gastrointestinal, neurological and cardiovascular disorders
06/21/2007WO2007068728A2 N-substituted pyrrolopyridinones active as kinase inhibitors
06/21/2007WO2007068704A1 Anti-myosin va sirna and skin depigmentation
06/21/2007WO2007068701A1 Aqueous-alcoholic depigmenting gel
06/21/2007WO2007068655A1 Micronization method
06/21/2007WO2007068641A1 Pyrrolo [2 , 3-b] pyridine derivatives as h3 receptor modulators
06/21/2007WO2007068637A1 Substituted pyrrolo-pyrazole derivatives active as kinase inhibitors
06/21/2007WO2007068621A1 Novel fused pyrrole derivatives
06/21/2007WO2007068620A1 Pyrrolo[2,3-c]pyridine derivatives
06/21/2007WO2007068619A1 Substituted pyrazolo [4,3-c] pyridine derivatives active as kinase inhibitors
06/21/2007WO2007068615A2 Hcv prodrug formulation
06/21/2007WO2007068580A1 Biphenyl derivatives as selective agonists of gamma rar receptor
06/21/2007WO2007068579A1 Biphenyl derivatives as selective agonists of gamma rar receptors
06/21/2007WO2007068577A1 Use of naveglitazar for preparing a pharmaceutical composition for use in the treatment of dermatological conditions
06/21/2007WO2007068552A1 Bicyclic heterocycles, medicaments containing said compounds, use thereof, and method for the production thereof
06/21/2007WO2007068495A1 Salts of clopidogrel with polynions and their use for manufacturing pharmaceutical formulations
06/21/2007WO2007068487A2 Tumour treatment with treg down-regulating active agents
06/21/2007WO2007068476A1 [ (1h- indol- 5 -yl) -heteroaryloxy] - (1-aza-bicyclo [3.3.1] nonanes as cholinergic ligands of the n-achr for the treatment of psychotic and neurodegenrative disorders.
06/21/2007WO2007068475A1 (1-aza-bicyclo[3.3.1] n0n-4-yl)-[5-(ih-indol-5-yl)-heteroaryl]-amines as cholinergic ligands of the n-achr for the treatment of psychotic and neurodegenerative disorders
06/21/2007WO2007068465A1 Tricyclic lactam derivatives, their manufacture and use as pharmaceutical agents
06/21/2007WO2007068462A2 Mtor inhibitors for the treatment of inflammatory bowel disease
06/21/2007WO2007068434A2 Medicament based on a monoester of steroids with long chain fatty acids
06/21/2007WO2007068418A1 Use of pyrrolo [2 , 3-b] pyridines to prepare a medicament for treating pain